Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01721044
Registration number
NCT01721044
Ethics application status
Date submitted
1/11/2012
Date registered
2/11/2012
Date last updated
18/09/2019
Titles & IDs
Public title
A Moderate to Severe Rheumatoid Arthritis Study
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Query!
Secondary ID [1]
0
0
I4V-MC-JADW
Query!
Secondary ID [2]
0
0
14058
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RA-BEACON
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Baricitinib
Treatment: Drugs - cDMARD
Placebo Comparator: Placebo - Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.
Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
Experimental: Baricitinib 2 mg - Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
Participants will continue to take background cDMARD therapy throughout study.
Experimental: Baricitinib 4 mg - Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
Participants will continue to take background cDMARD therapy throughout study.
Treatment: Drugs: Placebo
Administered orally
Treatment: Drugs: Baricitinib
Administered orally
Treatment: Drugs: cDMARD
Participants will continue to take background cDMARD therapy throughout study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg
Query!
Assessment method [1]
0
0
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinue study or drug or are rescued before analysis timepoint are deemed non-responders.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 4 mg
Query!
Assessment method [1]
0
0
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Query!
Timepoint [1]
0
0
Baseline, Week 12
Query!
Secondary outcome [2]
0
0
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count (DAS-28) High Sensitivity C-Reactive Protein (hsCRP) - Placebo Versus Baricitinib 4 mg
Query!
Assessment method [2]
0
0
DAS-28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), high sensitivity C-reactive protein (hsCRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-hsCRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Query!
Timepoint [2]
0
0
Baseline, Week 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission - Simplified Disease Activity Index (SDAI) =3.3 - Placebo Versus Baricitinib 4 mg
Query!
Assessment method [3]
0
0
The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score =3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving ACR20 Response - Placebo Versus Baricitinib 2 mg
Query!
Assessment method [4]
0
0
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Change From Baseline in HAQ-DI Score - Placebo Versus Baricitinib 2 mg
Query!
Assessment method [5]
0
0
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score. Total scores ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Query!
Timepoint [5]
0
0
Baseline, Week 12
Query!
Secondary outcome [6]
0
0
Change From Baseline in the DAS28 - hsCRP - Placebo Versus Baricitinib 2 mg
Query!
Assessment method [6]
0
0
DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*Patient's Global VAS+0.96. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Query!
Timepoint [6]
0
0
Baseline, Week 12
Query!
Secondary outcome [7]
0
0
Percentage of Participants Achieving ACR/EULAR Remission - SDAI =3.3 - Placebo Versus Baricitinib 2 mg
Query!
Assessment method [7]
0
0
The ACR/EULAR definitions of rheumatoid arthritis (RA) remission includes an index-based definition. The index-based definition of remission occurs with a SDAI score =3.3. The SDAI is a tool for measurement of disease activity in RA that integrates TJC28 (0 to 28), SJC28 (0 to 28), acute phase response using C-reactive protein (0.1 to 10.0 mg/dL), Patient's Global Assessment of Disease Activity using VAS (0 to 10.0 cm), and Physician's Global Assessment of Disease Activity using VAS (0 to 10.0 cm). Lower scores indicated less disease activity.
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving ACR20 Response
Query!
Assessment method [8]
0
0
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis. ACR20 Responder is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity using VAS, Patient's Global Assessment of Disease Activity using VAS, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.
Query!
Timepoint [8]
0
0
Week 24
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
Query!
Assessment method [9]
0
0
ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 Responder is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.
Query!
Timepoint [9]
0
0
Week 12 and Week 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Query!
Assessment method [10]
0
0
ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR70 Responder is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.
Query!
Timepoint [10]
0
0
Week 12 and Week 24
Query!
Secondary outcome [11]
0
0
Change From Baseline in DAS28 - Erythrocyte Sedimentation Rate (ESR)
Query!
Assessment method [11]
0
0
DAS28 consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), ESR (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using following formula: DAS28-ESR=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.70*natural log(ESR)+0.014*Patient's Global VAS. Total scores ranged from 1.0-9.4, where lower scores indicated less disease activity.
Query!
Timepoint [11]
0
0
Baseline, Week 12
Query!
Secondary outcome [12]
0
0
Change From Baseline in Clinical Disease Activity Index Score
Query!
Assessment method [12]
0
0
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Query!
Timepoint [12]
0
0
Baseline, Week 24
Query!
Secondary outcome [13]
0
0
Change From Baseline in Measures of SDAI Score
Query!
Assessment method [13]
0
0
The SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using visual analog scale (cm), and Physician's Global Assessment of Disease Activity using visual analog scale (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity.
The SDAI is expressed as a score on a scale with the minimum score=0 (best) to maximum score=86 (worst). A negative change from baseline indicates an improvement.
Query!
Timepoint [13]
0
0
Baseline, Week 24
Query!
Secondary outcome [14]
0
0
Percentage of Participants Achieving ACR/EULAR Remission - Boolean Remission
Query!
Assessment method [14]
0
0
The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 =1, SJC28 =1, acute phase response using C-reactive protein (milligrams per deciliter) =1, Patient's Global Assessment of Disease Activity using VAS (cm) =1.
Query!
Timepoint [14]
0
0
Week 24
Query!
Secondary outcome [15]
0
0
Change From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness
Query!
Assessment method [15]
0
0
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on that day. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Query!
Timepoint [15]
0
0
Baseline, Week 24
Query!
Secondary outcome [16]
0
0
Change From Baseline in Worst Tiredness Numeric Rating Scale (NRS)
Query!
Assessment method [16]
0
0
A participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no tiredness) and 10 representing (as bad as you can imagine). Participants rate their tiredness by selecting the one number that describes their worst level of tiredness during the past 24 hours. Total scores ranged from 0-10.
Query!
Timepoint [16]
0
0
Baseline, Week 24
Query!
Secondary outcome [17]
0
0
Change From Baseline in Worst Joint Pain NRS
Query!
Assessment method [17]
0
0
Participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing (no joint pain) and 10 representing (pain as bad as you can imagine). Participants rate their joint pain by selecting the one number that describes their worst level of joint pain during the past 24 hours. Total scores ranged from 0-10.
Query!
Timepoint [17]
0
0
Baseline, Week 24
Query!
Secondary outcome [18]
0
0
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale Scores
Query!
Assessment method [18]
0
0
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (Not at all) to 4 (Very much) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
Query!
Timepoint [18]
0
0
Baseline, Week 12, Week 24
Query!
Secondary outcome [19]
0
0
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
Query!
Assessment method [19]
0
0
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental [MCS] and physical [PCS]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status.
Query!
Timepoint [19]
0
0
Baseline, Week 12, Week 24
Query!
Secondary outcome [20]
0
0
Change From Baseline in European Quality of Life-5 Dimensions-5 Level Scores
Query!
Assessment method [20]
0
0
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 mm indicated the worst health you can imagine and 100 mm indicated the best health you can imagine.
Query!
Timepoint [20]
0
0
Baseline, Week 12, Week 24
Query!
Secondary outcome [21]
0
0
Percentage Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
Query!
Assessment method [21]
0
0
The WPAI-RA participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. Using 6 questions, it yields four types of scores: absenteeism (work time missed), presenteeism (impairment at work), work productivity loss (overall work impairment), and activity impairment, with outcomes expressed as impairment percentages. Percentage work time missed absenteeism: Q2/(Q2+Q4)*100, Percentage impairment while working presenteeism: Q5/10*100; Percentage overall work impairment work productivity loss: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))x(Q5/10)]*100; Percentage activity impairment activity impairment: Q6/10*100. Higher numbers indicate greater impairment and less productivity, that is, worse outcomes.
Query!
Timepoint [21]
0
0
Baseline, Week 12, Week 24
Query!
Secondary outcome [22]
0
0
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of Baricitinib
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.
Query!
Secondary outcome [23]
0
0
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
Week 0 (Baseline): 15 min. post-dose, 1 hour post-dose. Week 4 (Day 28 ±2 days): 2 to 4 hours post-dose. Week 8 (Day 56 ±3 days): 4 to 6 hours post-dose. Week 12 (Day 84 ±3 days): Pre-dose. Week 24 (Day 168 ±5 days): Pre-dose.
Query!
Eligibility
Key inclusion criteria
- Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American
College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria
for the Classification of RA
- Have moderately to severely active RA defined as the presence of at least 6/68 tender
joints and at least 6/66 swollen joints
- Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP)
measurement = (greater than or equal to) 1 times the upper limit of normal (ULN)
- Have been treated at approved doses with at least 1 biologic tumor necrosis factor
(TNF)- alpha inhibitor for at least 3 months and either:
- experienced insufficient efficacy or loss of efficacy
- experienced intolerance of such treatment
- Have had regular use of at least 1 conventional disease-modifying antirheumatic drugs
(cDMARD) for at least the 12 weeks prior to study entry with a continuous, nonchanging
dose for at least 8 weeks prior to study entry
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have received a biologic treatment for RA within 28 days of planned randomization;
have received rituximab within 6 months of planned randomization
- Are currently receiving corticosteroids at doses > (greater than) 10 mg per day of
prednisone (or equivalent) or have been receiving an unstable dosing regimen of
corticosteroids within 2 weeks of study entry or within 6 weeks of planned
randomization
- Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have
been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or
within 6 weeks of planned randomization
- Are currently receiving concomitant treatment with methotrexate (MTX),
hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs
- Have received any parenteral corticosteroid administered by intramuscular or
intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior
to planned randomization or are anticipated to require parenteral injection of
corticosteroids during the study
- Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic
acid within 2 weeks prior to study entry or within 6 weeks prior to planned
randomization
- Have active fibromyalgia that, in the investigator's opinion, would make it difficult
to appropriately assess RA activity for the purposes of this study
- Have a diagnosis of any systemic inflammatory condition other than RA, such as, but
not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
ulcerative colitis, psoriatic arthritis, active vasculitis or gout (participants with
secondary Sjogren's syndrome are not excluded.)
- Have a diagnosis of Felty's syndrome
- Have had any major surgery within 8 weeks of study entry or will require major surgery
during the study that, in the opinion of the investigator in consultation with Lilly
or its designee, would pose an unacceptable risk to the participant
- Have experienced any of the following within 12 weeks of study entry: myocardial
infarction, unstable ischemic heart disease, stroke, or have New York Heart
Association stage IV heart failure
- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute a risk when taking investigational product or could interfere with the
interpretation of data
- Are largely or wholly incapacitated permitting little or no self care, such as, being
bedridden or confined to a wheelchair
- Have an estimated glomerular filtration rate (eGFR) based on the most recent available
serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <
(less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)
- Have a history of chronic liver disease with the most recent available aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the
most recent available total bilirubin =1.5 times the ULN
- Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive
of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or
have active primary or recurrent malignant disease; or have been in remission from
clinically significant malignancy for <5 years
- Have been exposed to a live vaccine within 12 weeks prior to planned randomization or
are expected to need/receive a live vaccine during the course of the study (with the
exception of herpes zoster vaccination)
- Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
infection
- Have had symptomatic herpes zoster infection within 12 weeks prior to study entry
- Have a history of disseminated/complicated herpes zoster (eg, multidermatomal
involvement, ophthalmic zoster, central nervous system involvement, postherpetic
neuralgia)
- Are immunocompromised and, in the opinion of the investigator, are at an unacceptable
risk for participating in the study
- Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human
immunodeficiency virus (HIV)
- Have screening laboratory test values, including thyroid-stimulating hormone (TSH),
outside the reference range for the population or investigative site that, in the
opinion of the investigator, pose an unacceptable risk for the participant's
participation in the study
- Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the
investigator or the sponsor, are clinically significant and indicate an unacceptable
risk for the participant's participation in the study (e.g. Fridericia's corrected QT
interval >500 millisecond [msec])
- Have symptomatic herpes simplex at the time of study enrollment
- Have evidence of active or latent tuberculosis (TB)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
527
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kogarah
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Maroochydore
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
04266-010 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Delaware
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Wisconsin
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Rosario
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
San Miguel De Tucuman
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Graz
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Vienna
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Brussels
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Mons
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Ontario
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
Frederiksberg
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Glostrup
Query!
Country [29]
0
0
Denmark
Query!
State/province [29]
0
0
Odense
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Montpellier
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Orleans
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Paris
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Rennes
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Tours
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Dresden
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Hamburg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Heidelberg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Würzburg
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Athens
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Heraklion
Query!
Country [41]
0
0
Greece
Query!
State/province [41]
0
0
Kifissia
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Larissa
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Ashkelon
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Beer Yaakov
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Haifa
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Jerusalem
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Kfar Saba
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Petah Tikva
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Tel Aviv
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Firenze
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Pisa
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Rome
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Chiba
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Fukuoka
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Hiroshima
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Hokkaido
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Japan
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Kagawa
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Kumamoto
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Nagasaki
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Okayama
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Saitama
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Tokyo
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Seoul
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Guadalajara
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Mexico City
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Monterrey
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
San Luis Potosi
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Ubbergen
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Gdansk
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Nadarzyn
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Warsaw
Query!
Country [73]
0
0
Puerto Rico
Query!
State/province [73]
0
0
Caguas
Query!
Country [74]
0
0
Puerto Rico
Query!
State/province [74]
0
0
San Juan
Query!
Country [75]
0
0
Puerto Rico
Query!
State/province [75]
0
0
Santurce
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
La Vila Joiosa
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Santander
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Sevilla
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Valencia
Query!
Country [80]
0
0
Switzerland
Query!
State/province [80]
0
0
Fribourg
Query!
Country [81]
0
0
Switzerland
Query!
State/province [81]
0
0
Lausanne
Query!
Country [82]
0
0
Switzerland
Query!
State/province [82]
0
0
Zürich
Query!
Country [83]
0
0
Turkey
Query!
State/province [83]
0
0
Edirne
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Gaziantep
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Tyneside
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
West Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is
superior to placebo in the treatment of participants with moderately to severely active
Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor
(TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic
drugs (cDMARDs).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01721044
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01721044
Download to PDF